Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Haemonetics Corporation (NYSE:HAE) has received a consensus rating of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $84.40.

HAE has been the topic of a number of research analyst reports. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. CJS Securities raised Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. upped their price objective on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Mizuho lifted their target price on Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Finally, BTIG Research reissued a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, January 9th.

Haemonetics Stock Performance

Shares of HAE stock opened at $68.84 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The firm has a 50-day moving average of $79.33 and a 200-day moving average of $65.78. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company has a market cap of $3.22 billion, a P/E ratio of 20.13, a P/E/G ratio of 1.43 and a beta of 0.29.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. During the same period in the prior year, the firm posted $1.12 EPS. The firm’s quarterly revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts forecast that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in shares of Haemonetics by 372.8% during the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares during the last quarter. River Road Asset Management LLC grew its position in Haemonetics by 18.7% during the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after purchasing an additional 260,624 shares during the period. Geode Capital Management LLC grew its position in Haemonetics by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock worth $92,873,000 after purchasing an additional 23,257 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Haemonetics by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after buying an additional 26,763 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Haemonetics by 11.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,060,790 shares of the medical instruments supplier’s stock valued at $51,777,000 after buying an additional 111,307 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.